Haloperidol cytotoxicity and its relation to oxidative stress

Mini-Reviews in Medicinal Chemistry

Volumn 13, Issue 14, 2013, Pages 1993-1998

  Raudenska, Martina ^a   Gumulec, Jaromir ^a   Babula, Petr ^b   Stracina, Tibor ^a   Sztalmachova, Marketa ^a,c   Polanska, Hana ^a,c   Adam, Vojtech ^c,d   Kizek, Rene ^c,d   Novakova, Marie ^a,e   Masarik, Michal ^a  

^a MASARYK UNIVERSITY   (Czech Republic)

^b UNIVERSITY OF VETERINARY AND PHARMACEUTICAL SCIENCES   (Czech Republic)

^c MENDEL UNIVERSITY IN BRNO   (Czech Republic)

^d BRNO UNIVERSITY OF TECHNOLOGY   (Czech Republic)

^e International Clinical Research Center   (Czech Republic)

Author keywords

Arrhytmia; Cardiotoxicity; Dopamine; Haloperidol; Oxidative stress; Torsade de Pointes

Indexed keywords

CATALASE; DOPAMINE 2 RECEPTOR; DOPAMINE TRANSPORTER; ERYTHROCYTE MEMBRANE PROTEIN BAND 4,1 LIKE PROTEIN 1; GLUTATHIONE PEROXIDASE; HALOPERIDOL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INOSITOL 1, 4, 5 TRISPHOSPHATE; MEMBRANE PROTEIN; REACTIVE OXYGEN METABOLITE; SEMIQUINONE; SERUM AND GLUCOCORTICOID REGULATED KINASE 1; SIGMA 1 OPIATE RECEPTOR; SUPEROXIDE DISMUTASE; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

CARDIOTOXICITY; CELL DEATH; CELL PROTECTION; CYTOTOXICITY; EXTRAPYRAMIDAL SYMPTOM; GENE EXPRESSION; HEART ARRHYTHMIA; HUMAN; LIPID PEROXIDATION; NECROSIS; NEUROTOXICITY; OXIDATIVE STRESS; QT INTERVAL; REVIEW;

ANTIPSYCHOTIC AGENTS; DELIRIUM; GENE EXPRESSION REGULATION; HALOPERIDOL; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; NF-KAPPA B; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES;

EID: 84892977849     PISSN: 13895575     EISSN: 18755607     Source Type: Journal    
DOI: 10.2174/13895575113136660100     Document Type: Review

References (50)

1. Svestka, J. In: Psychiatrie; Raboch, J.; Zvolsky, P., Eds.; Galén: Praha, 2001; p 622.
2. Sulcova, A.; Gaier, N.; Dolezal, T.; Krsiak, M.; Votava, M.; Hess, L.; Kmonickova, E.; Sustkova, M. In: Základní a aplikovaná farmakologie; Lincová, D.; Farghali, H., Eds.; Galén: Praha, 2007.
3. Igarashi, K.; Kasuya, F.; Fukui, M.; Usuki, E.; Castagnoli, N. Studies on the metabolism of haloperidol (HP)-the role of CYP3A in the production of the neurotoxic pyridinium metabolite HPP+ found in rat-brain following IP administration of HP. Life Sci., 1995, 57(26), 2439-2446.
4. Fang, J.; Baker, G. B.; Silverstone, P. H.; Coutts, R. T. Involvement of CYP3A4 and CYP2D6 in the metabolism of haloperidol. Cell. Mol. Neurobiol., 1997, 17(2), 227-233.
5. Pan, L. P.; Wijnant, P.; De Vriendt, C.; Rosseel, M. T.; Belpaire, F. M. Characterization of the cytochrome P450 isoenzymes involved in the in vitro N-dealkylation of haloperidol. Br. J. Clin. Pharmacol., 1997, 44(6), 557-564.
6. Holley, F. O.; Magliozzi, J. R.; Stanski, D. R.; Lombrozo, L.; Hollister, L. E. Haloperidol kinetics after oral and intravenous doses. Clin. Pharmacol. Ther., 1983, 33(4), 477-484.
7. Glennon, R. A. Binding characteristics of α2 receptor ligands. Braz. J. Pharm. Sci., 2005, 41(1), 1-12.
8. Cobos, E. J.; Entrena, J. M.; Nieto, F. R.; Cendan, C. M.; Del Pozo, E. Pharmacology and Therapeutic Potential of Sigma(1) Receptor Ligands. Curr. Neuropharm., 2008, 6(4), 344-366.
9. Stone, J. M.; Arstad, E.; Erlandsson, K.; Waterhouse, R. N.; Ell, P. J.; Pilowsky, L. S. (123)I TPCNE-A novel SPET tracer for the sigma-1 receptor: First human studies and in vivo haloperidol challenge. Synapse, 2006, 60(2), 109-117.
10. Shivakumar, B. R.; Ravindranath, V. Oxidative stress-induced by administration of the neuroleptic drug haloperidol is attenuated by higher doses of haloperidol. Brain Res., 1992, 595(2), 256-262.
11. Casey, D. E. Neuropsychiatry of involuntary movement disorders. tardive dyskinesia. Curr. Opin. Psychiatry, 1991, 4(1), 86-89.
12. Fayer, S. A. Torsades de pointes ventricular tachyarrhythmia associated with haloperidol. J. Clin. Psychopharmacol., 1986, 6(6), 375-6.
13. Hunt, N.; Stern, T. A. The association between intravenous haloperidol and torsades-de-pointes-3 cases and a literature-review. Psychosomatics, 1995, 36(6), 541-549.
14. Henderson, R. A.; Lane, S.; Henry, J. A. Life-threatening ventricular arrhythmia (torsades-de-pointes) after haloperidol overdose. Hum. Exp. Toxicol., 1991, 10(1), 59-62.
15. Blom, M. T.; Bardai, A.; van Munster, B. C.; Nieuwland, M. I.; de Jong, H.; van Hoeijen, D. A.; Spanjaart, A. M.; de Boer, A.; de Rooij, S. E.; Tan, H. L. Differential Changes in QTc Duration during In-Hospital Haloperidol Use. PLoS ONE, 2011, 6(9), e23728.
16. Jabotinskyrubin, K.; Durst, R.; Levitin, L. A.; Moscovich, D. G.; Silver, H.; Lerner, J.; Vanpraag, H.; Gardner, E. L. Effects of haloperidol on human plasma magnesium. J. Psychiatr. Res., 1993, 27(2), 155-159.
17. Satoh, Y.; Sugiyama, A.; Tamura, K.; Hashimoto, K. Effect of magnesium sulfate on the haloperidol-induced QT prolongation assessed in the canine in vivo model under the monitoring of monophasic action potential. Jpn. Circ. J., 2000, 64(6), 445-451.
18. Furutani, K.; Inanobe, A.; Hibino, H.; Kurachi, Y. Haloperidol blocks ATP-sensitive potassium channels. J. Pharmacol. Sci., 2010, 112, 252P-252P.
19. Bebarova, M.; Matejovic, P.; Pasek, M.; Novakova, M. Effect of sigma ligand haloperidol on transient outward potassium current in RAT cardiomyocytes. J. Mol. Cell. Cardiol., 2005, 39(1), 173-173.
20. Bebarova, M.; Matejovic, P.; Pasek, M.; Novakova, M. Effect of haloperidol on transient outward potassium current in rat ventricular myocytes. Eur. J. Pharmacol., 2006, 550(1-3), 15-23.
21. Behl, C.; Lezoualch, F.; Widmann, M.; Rupprecht, R.; Holsboer, F. Oxidative stress-resistant cells are protected against haloperidol toxicity. Brain Res., 1996, 717(1-2), 193-195.
22. Megalizzi, V.; Le Mercier, M.; Decaestecker, C. Sigma receptors and their ligands in cancer biology: overview and new perspectives for cancer therapy. Med. Res. Rev., 2012, 32(2), 410-427.
23. Emsley, R. A.; Roberts, M. C.; Rataemane, S.; Pretorius, J.; Oosthuizen, P. P.; Turner, J.; Niehaus, D. J. H.; Keyter, N.; Stein, D. J. Ethnicity and treatment response in schizophrenia: A comparison of 3 ethnic groups. J. Clin. Psychiatry, 2002, 63(1), 9-14.
24. Lin, K. M. Psychopharmacology in cross-cultural psychiatry. Mt. Sinai J. Med., 1996, 63(5-6), 283-284.
25. Potkin, S. G.; Shen, Y. C.; Pardes, H.; Phelps, B. H.; Zhou, D. F.; Shu, L. N.; Korpi, E.; Wyatt, R. J. Haloperidol concentrations elevated in chinese patients. Psychiatry Res., 1984, 12(2), 167-172.
26. Jann, M. W.; Chang, W. H.; Davis, C. M.; Chen, T. Y.; Deng, H. C.; Lung, F. W.; Ereshefsky, L.; Saklad, S. R.; Richards, A. L. Haloperidol and reduced haloperidol plasma-levels in Chinese vs non-Chinese psychiatric-patients. Psychiatry Res., 1989, 30(1), 45-52.
27. Ananth, J.; Lin, K. M. Physical and ethnic variables in dosage for asians. Am. J. Psychiatry, 1982, 139(4), 539-540.
28. Lin, K. M.; Finder, E. Neuroleptic dosage for asians. Am. J. Psychiatry, 1983, 140(4), 490-491.
29. Binder, R. L.; Levy, R. Extrapyramidal reactions in Asians. Am. J. Psychiatry, 1981, 138(9), 1243-1244.
30. Lin, K. M.; Poland, R. E.; Nuccio, I.; Matsuda, K.; Hathuc, N.; Su, T. P.; Fu, P. A longitudinal assessment of haloperidol doses and serum concentrations in asian and caucasian schizophrenic-patients. Am. J. Psychiatry, 1989, 146(10), 1307-1311.
31. Hodnick, W. F.; Duval, D. L.; Pardini, R. S. Inhibition of mitochondrial respiration and cyanide-stimulated generation of reactive oxygen species by selected flavonoids. Biochem. Pharmacol., 1994, 47(3), 573-580.
32. Barzilai, A.; Yamamoto, K. I. DNA damage responses to oxidative stress. DNA Repair, 2004, 3(8-9), 1109-1115.
33. Mark, R. J.; Hensley, K.; Butterfield, D. A.; Mattson, M. P. Amyloid beta-peptide impairs ion-motive ATPase activities: evidence for a role in loss of neuronal Ca2+ homeostasis and cell death. J. Neurosci., 1995, 15(9), 6239-49.
34. Oneill, L. A. J.; Kaltschmidt, C. NF-kappa B: A crucial transcription factor for glial and neuronal cell function. Trends Neurosci., 1997, 20(6), 252-258.
35. Lawler, J. M.; Powers, S. K. Oxidative stress, antioxidant status, and the contracting diaphragm. Can. J. Appl. Physiol., 1998, 23(1), 23-55.
36. Vaziri, N. D.; Dicus, M.; Ho, N. D.; Boroujerdi-Rad, L.; Sindhu, R. K. Oxidative stress and dysregulation of superoxide dismutase and NADPH oxidase in renal insufficiency. Kidney Int., 2003, 63(1), 179-185.
37. Baeuerle, P. A.; Henkel, T. Function amd activation of NF-kappa-B in the immune-system. Annu. Rev. Immunol., 1994, 12, 141-179.
38. Li, Y. C.; Zhang, W. X.; Mantell, L. L.; Kazzaz, J. A.; Fein, A. M.; Horowitz, S. Nuclear factor-kappa B is activated by hyperoxia but does not protect from cell death. J. Biol. Chem., 1997, 272(33), 20646-20649.
39. Post, A.; Holsboer, F.; Behl, C. Induction of NF B Activity during Haloperidol-Induced Oxidative Toxicity in Clonal Hippocampal Cells: Suppression of NF B and Neuroprotection by Antioxidants. J. Neurosci., 1998, 18(20), 8236-8246.
40. Halliwell, B. Reactive Oxygen Species and the Central Nervous System. J. Neurochem., 1992, 59(5), 1609-1623.
41. Bellamy, C. J.; Kane-Gill, S. L.; Falcione, B. A.; Seybert, A. L. Neuroleptic Malignant Syndrome in Traumatic Brain Injury Patients Treated With Haloperidol. J. Trauma Inj. Infect. Crit. Care., 2009, 66(3), 954-958.
42. Yen, H. L.; Tsai, S. C.; Sung, M. L. Neuroleptic malignant syndrome in a head injury patient treated with haloperidol. Eur. J. Neurol., 2011, 18, 314-314.
43. Rafalowska, U.; Liu, G. J.; Floyd, R. A. Peroxidation induced changes in synaptosomal transport of dopamine and gammaaminobutyric acid. Free Radic. Biol. Med., 1989, 6(5), 485-492.
44. Egan, M. F.; Hyde, T. M.; Albers, G. W.; Elkashef, A.; Alexander, R. C.; Reeve, A.; Blum, A.; Saenz, R. E.; Wyatt, R. J. Treatment of tardive-dyskinesia with vitamin-E. Am. J. Psychiatry, 1992, 149(6), 773-777.
45. Burkhardt, C.; Kelly, J. P.; Lim, Y. H.; Filley, C. M.; Parker, W. D. Neuroleptic medications inhibit complex-I of the electron-transport chain. Ann. Neurol., 1993, 33(5), 512-517.
46. Lidow, M. S.; GoldmanRakic, P. S. Differential regulation of D-2 and D-4 dopamine receptor mRNAs in the primate cerebral cortex vs. neostriatum: Effects of chronic treatment with typical and atypical antipsychotic drugs. J. Pharmacol. Exp. Ther., 1997, 283(2), 939-946.
47. Moran, L. B.; Graeber, M. B. Towards a pathway definition of Parkinson's disease: a complex disorder with links to cancer, diabetes and inflammation. Neurogenetics, 2008, 9(1), 1-13.
48. Novakova, M.; Sedlakova, B.; Sirova, M.; Fialova, K.; Krizanova, O. Haloperidol increases expression of the inositol 1, 4, 5-trisphosphate receptors in rat cardiac atria, but not in ventricles. Gen. Physiol. Biophys., 2010, 29(4), 381-389.
49. James, A. B.; Conway, A. M.; Morris, B. J. Regulation of the neuronal proteasome by Zif268 (Egr1). J. Neurosci., 2006, 26(5), 1624-1634.
50. Coffer, P. J.; Burgering, B. M. T. Forkhead-box transcription factors and their role in the immune system. Nat. Rev. Immunol., 2004, 4(11), 889-899.